| ¿µ¹® | hypoxia | ÇÑ±Û | Àú»ê¼ÒÁõ |
|---|---|---|---|
| ¼³¸í | »ê¼Ò¿î¹Ý°ú Ȱ¿ë °úÁ¤¿¡ Àå¾Ö¸¦ ¹ß»ýÇÏ¿©, µ¿¸ÆÇ÷ »ê¼ÒÇÔ·®(PaO2)ÀÌ °¨¼ÒÇϸç, Á¶Á÷ ¼ÓÀÇ »ê¼Ò°¡ Á¤»óÄ¡ ÀÌÇÏ·Î °¨¼ÒÇÑ »óÅÂ. ´ëº°ÇÏ¸é ¨ç Àú»ê¼Ò¼ºÀú»ê¼ÒÁõ, ¨è ºóÇ÷Àú»ê¼ÒÁõ, ¨é ¿ïÇ÷Àú»ê¼ÒÁõ, ¨ê Á¶Á÷µ¶¼ºÀú»ê¼ÒÁõ, ¨ë ¼ö¿ë¼º Àú»ê¼ÒÁõÀ» ºÐ·ùµÈ´Ù. ÃʱâÁõ»óÀº ÀǽÄÈ¥¶õ, µÎÅë, ¾îÁö·³Áõ, ±¸¿ª, °¡»Û È£Èí, ºü¸¥ ¸Æ µîÀ¸·Î, Áõ»óÀÌ ÁøÇàÇϸé û»öÁõ(Ç÷Áõ ȯ¿ø Hb °¡ 5g/100mL ÀÌ»ó), ÀǽļҽÇ, °æ·Ã, ´À¸°¸Æ, ºÎÁ¤¸Æ, È£Èí¾ïÁ¦, ½ÉÀåÁ¤Áö¿¡ À̸¥´Ù. »ê¼Ò¿ä¹ý, ±â°èÀû ÀΰøÈ£ÈíÀ» ½Ç½ÃÇÑ´Ù. ±× Á¾·ù¸¦ ¿øÀκ°·Î ºÐ·ùÇÏ¸é ´ÙÀ½°ú °°´Ù. ¨ç Àú»ê¼Ò¼ºÀú»ê¼ÒÁõ(hypoxic hypoxia): µ¿¸ÆÇ÷ÀÇ »ê¼ÒºÐ¾ÐÀÌ °¨¼ÒµÇ¾î ÃÊ·¡µÈ Àú»ê¼ÒÁõÀ¸·Î ÈíÀÔ °ø±â ÁßÀÇ »ê¼Ò ³óµµ°¡ °¨¼ÒÇÑ °æ¿ì, È£Èí ÁßÃß¾ïÁ¦-±âµµÆó¼â-È£Èí±Ù¸¶ºñ µî ÆóÆ÷ȯ±â°¡ °¨¼ÒÇÑ °æ¿ì, ¹«±âÆó-Æó·Å-ÆóºÎÁ¾ µî ÆóÆ÷¿¡¼ÀÇ °¡½º ±³È¯ÀÌ ºÎÀûÀýÇÏ¿© ÀϾ´Â °æ¿ì, °í¿-½ÅÁø´ë»çÇ×Áø µî Á¶Á÷ÀÇ »ê¼Ò ¼Ò¸ð°¡ Áõ°¡ÇÏ¿© ÀϾ´Â °æ¿ì, ÀÌ»êÈÁúÈ£(N2O)¸¦ ÀÌ¿ëÇÑ Àü½Å¸¶Ãë ÈÄ¿¡ µå¹°°Ô ³ªÅ¸³ª´Â È®»ê¼º Àú»ê¼ÒÁõ µî¿¡ ÀÇÇØ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ¨è ºóÇ÷Àú»ê¼ÒÁõ(anemic hypoxia) : Ç÷»ö¼Ò°¡ Á¤»ó ÀÌÇÏ·Î °¨¼ÒÇÑ °æ¿ì, ÀÏ»êÈ Åº¼ÒÁßµ¶Ã³·³ Ç÷»ö¼Ò°¡ »ê¼Ò¸¦ ¿î¹ÝÇÒ ¼ö ¾ø´Â °æ¿ì¿¡ ³ªÅ¸³ª´Â Àú»ê¼ÒÁõÀ¸·Î¼ »ê¼ÒºÐ¾ÐÀº Á¤»ó ¹üÀ§ ³»¿¡ ÀÖÀ¸³ª µ¿¸ÆÇ÷ÀÇ »ê¼Ò ÇÔ·®ÀÌ Å©°Ô °¨¼ÒµÇ¾î ÀÖ´Â °æ¿ì°¡ ´ëºÎºÐÀÌ´Ù. ¨é ¿ïÇ÷Àú»ê¼ÒÁõ(stagnant hypoxia) : µ¿¸ÆÇ÷ÀÇ »ê¼ÒºÐ¾ÐÀº Á¤»óÀ̳ª Á¶Á÷ÀÇ Ç÷¾×¼øÈ¯ÀÌ Àå¾Ö¸¦ ¹Þ¾Æ ³ªÅ¸³ª´Â Àú»ê¼ÒÁõÀ¸·Î ½É¹ÚÃâ·®ÀÌ °¨¼ÒÇÏ¿© ¿À´Â °æ¿ìµµ ÀÖ°í, »öÀüÁõ-¿Ü»ó-Ç÷°ü¼öÃà-Á¤¸ÆÆó¼â µî¿¡ ÀÇÇØ ¹ß»ýÇÒ ¼öµµ ÀÖ´Ù. ¨ê Á¶Á÷µ¶¼ºÀú»ê¼ÒÁõ(histotoxic hypoxia) : »ç¸³Ã¼ÀÇ »ê¼Ò ÀÌ¿ë·üÀÌ ³·¾ÆÁø °æ¿ì¿¡ ³ªÅ¸³´Ù. Ç÷°ü È®ÀåÁ¦¸¦ °ú·® »ç¿ëÇÏ°Ô µÇ¸é ¼¼Æ÷ ³» È¿¼ÒÀÇ µ¶¼º¿¡ ÀÇÇØ Àú»ê¼ÒÁõÀÌ ¿Ã ¼ö ÀÖ´Ù. |
||
| AGD | agar gel diffusion; agarose diffusion; alpha-ketoglutarate dehydrogenase |
|---|---|
| DP | data processing; deep pulse; definitive procedure; degradation product; degree of polymerization; de... |
| DC | 1) Direct Current 2) Diffusion Capacity |
| ID | 1) Immuno-Diffusion 2) Intra-Dermal; Çdz»·Î 3) Intra-Dural... |
| AD | accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade... |
| CH | Chronic hypoxia |
|---|---|
| H | Hypoxia |
| HYP | Hypoxia |
| HIF-1 | Hypoxia Inducible Factor-1 |
| HIF | Hypoxia inducible factor |
| diffusion hypoxia | Abrupt transient decrease in alveolar oxygen tension when room air is inhaled at the conclusion of a nitrous oxide anaesthesia, because nitrous oxide diffusing out of the blood dilutes the alveolar oxygen. (05 Mar 2000) |
|---|
| anaemic hypoxia | Hypoxia resulting from a decreased concentration of functional haemoglobin or a reduced number of erythrocytes; it is caused by haemorrhage or anaemia of various types, or by poisoning with CO2, nitrites, or chlorates. (05 Mar 2000) |
|---|---|
| cell hypoxia | A condition of decreased oxygen content at the cellular level. (12 Dec 1998) |
| cerebral hypoxia | A lack of oxygen to the cerebral hemispheres (the brain). Depending on the duration and extent of hypoxia, symptoms can be mild (for example lethargy) or serious neurologic damage can result (for example coma, seizures, death). (27 Sep 1997) |
| hypoxia | Reduction of oxygen supply to tissue below physiological levels despite adequate perfusion of the tissue by blood. (cf. Anoxia). (18 Nov 1997) |
| hypoxia-ischemia | See hypoxia. Ischemia refers to blood flow to cells and organs that is not sufficient to maintain their normal function. (12 Dec 1998) |
| hypoxia warning system | A device designed to produce an audio or visual signal at a predetermined level of oxygen partial pressure; ideally, the system would warn of impending hypoxia in time for corrective action to be taken. (05 Mar 2000) |
| hypoxic hypoxia | Hypoxia resulting from a defective mechanism of oxygenation in the lungs; may be caused by a low tension of oxygen, abnormal pulmonary function or respiratory obstruction, or a right-to-left shunt in the heart. (05 Mar 2000) |
| stagnant hypoxia | Tissue hypoxia characterised not by tissue oligaemia (tissue blood volume being normal or even increased), but by intravascular stasis due to impairment of venous outflow or (in some instances) to decreased arterial inflow. (05 Mar 2000) |
| delayed coma after hypoxia | Coma that develops a few days to 3 weeks after an acute hypoxic insult; the latter was usually severe enough to cause an initial bout of coma, which cleared, and was followed by a transient interval of apparent normality. Synonym: severe postanoxic encephalopathy. (05 Mar 2000) |
| ischemic hypoxia | Tissue hypoxia characterised by tissue oligaemia and caused by arterial or arteriolar obstruction or vasoconstriction. (05 Mar 2000) |
| oxygen affinity hypoxia | Hypoxia due to reduced ability of haemoglobin to release oxygen. (05 Mar 2000) |
| ambipolar diffusion | <radiobiology> Diffusion process in which buildup of spatial charge creates electric fields which cause electrons and ions to leave the plasma at the same rate. (Such electric fields are self-generated by the plasma and act to preserve charge neutrality.) (09 Oct 1997) |
| anomalous diffusion | <radiobiology> Diffusion in most plasma devices, particularly tokamaks, is higher than what one would predict from understood causes. The observed, typical diffusion is referred to as anomalous because it has not yet been explained. Anomalous diffusion includes all diffusion which is not due to collisions and geometric effects. While such effects were not understood when the term was coined, and most still are not, diffusion due to well-understood wave phenomena is still 'anomalous'. Classical diffusion and Neo-classical diffusion are the two well-understood diffusion theories, although neither is adequate to fully explain the observed anomalous diffusion. See: entries for classical diffusion and neoclassical diffusion. Anomalous resistivity (09 Oct 1997) |
| bohm diffusion | <radiobiology> A rapid loss of plasma across magnetic field lines caused by microinstabilities. Theory formulated by the physicist David Bohm. Semiempirical formula for the diffusion coefficient given by Bohm in 1946 (noted by Bohm, Burhop, and Massey, who were developing a magnetic arc for use in uranium isotope separation). Bohm diffusion was proposed (not derived from first principles) to scale as 1/B rather than the 1/B^2 scaling predicted by classical diffusion. A 1/B scaling results from assuming that particles diffuse across field lines at an optimum rate (effective collision frequency=cyclotron frequency). The 1/B scaling is observed (approximately) in most reactors. See: diffusion, microinstabilities, field lines. (09 Oct 1997) |
| gel diffusion | Diffusion in a gel, as in the case of gel diffusion precipitin tests in which the immune reactants diffuse in agar. See: immunodiffusion. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|